دورية أكاديمية
أعرض في EDS

Serum Apo Lipoprotein E, Apo Lipoprotein E Gene Polymorphisms, and Parkinson's Disease.

التفاصيل البيبلوغرافية
العنوان: Serum Apo Lipoprotein E, Apo Lipoprotein E Gene Polymorphisms, and Parkinson's Disease.
المؤلفون: Fahmy EM; Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt., Rabah AM; Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt., Hashem SE; Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt., Rashed LA; Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt., Deraz HA; Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt., Ismail RS; Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt.
المصدر: Neurology India [Neurol India] 2024 Mar 01; Vol. 72 (2), pp. 319-325. Date of Electronic Publication: 2024 Apr 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Publications Country of Publication: India NLM ID: 0042005 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-4022 (Electronic) Linking ISSN: 00283886 NLM ISO Abbreviation: Neurol India Subsets: MEDLINE
أسماء مطبوعة: Publication: Mumbai : Medknow Publications
Original Publication: Bombay : Neurological Society of India
مواضيع طبية MeSH: Apolipoproteins E*/genetics , Apolipoproteins E*/blood , Parkinson Disease*/genetics , Parkinson Disease*/blood , Polymorphism, Genetic*/genetics, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Genetic Predisposition to Disease ; Genotype ; Severity of Illness Index
مستخلص: Background: A central role for apolipoprotein E (APOE) has been suggested in modulating processes of neurodegeneration.
Objective: To study the association between serum APOE levels, APOE gene polymorphisms, and Parkinson's disease (PD).
Material and Methods: Fifty-five patients with PD and 30 healthy subjects were enrolled. PD patients were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS), Modified Hoehn and Yahr scale, and Schwab-England Activities of Daily Living scale. Serum APOE level and genotyping for APOE polymorphisms were done for PD patients and controls using enzyme-linked immunosorbent assay and polymerase chain reaction, respectively.
Results: Mean serum APOE level was significantly higher in PD patients compared with healthy controls. APOE ε2/4 genotype was present in a significantly higher proportion of patients compared with controls. APOE ε4 allele was significantly associated with a higher score on the "mentation, behavior, and mood section" of UPDRS compared with ε2 allele. APOE ε2 allele was significantly associated with a shorter disease duration compared with ε3 and ε4 alleles. Mean serum APOE level was significantly higher in patients presenting predominantly by rigidity and bradykinesia compared with those presenting predominantly by tremors. Serum APOE level was positively correlated with mean scores of "mentation, behavior, and mood section" of UPDRS and disease duration. Serum APOE level was a significant predictor for the scores of "mentation, behavior, and mood section" of UPDRS.
Conclusion: APOE ε2/4 genotype might be a susceptibility variant for PD. There may be a possible role for APOE in modulating the process of neurodegeneration in PD.
(Copyright © 2024 Copyright: © 2024 Neurology India, Neurological Society of India.)
References: Emamzadeh FN. Role of apolipoproteins and α-synuclein in Parkinson’s disease. J Mol Neurosci 2017;62:344–55.
Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis 2018;109:249–57.
Huang Y, Mahley RW. Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases. Neurobiol Dis 2014;72:3–12.
Dose J, Huebbe P, Nebel A, Rimbach G. APOE genotype and stress response-A mini review. Lipids Health Dis 2016;15:1–5.
Gallardo G, Schlüter OM, Südhof TC. A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat Neurosci 2008;11:301–8.
Chetty PS, Mayne L, Lund-Katz S, Englander SW, Phillips MC. Helical structure, stability, and dynamics in humanapolipoprotein E3 and E4 by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci 2017;114:968–73.
Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004;62:2005–9.
Singh NK, Banerjee BD, Bala K, Dung AA, Chhillar N. APOE and LRPAP1 gene polymorphism and risk of Parkinson’s disease. Neurol Sci 2014;35:1075–81.
Pierzchlińska A, Białecka M, Kurzawski M, Sławek J. The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson’s disease. Neurol Neurochir Pol 2018;52:477–82.
Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med 2020;12:eaay3069.
Van Giau V, Bagyinszky E, An SS, Kim SY. Role of apolipoprotein E in neurodegenerative diseases. Neuropsychiatr Dis Treat 2015;11:1723–37.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.
Fahn S, Elton RL; Members of the UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DM, Goldstein M, editors. Recent Development in Parkinson’s Disease, Vol. 2. Florham Park, NJ: MacMillan Health Care Information; 1987. p. 153–63, 293–304.
Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord 2004;19:1020–8.
Schwab RS. Projection technique for evaluating surgery in Parkinson’s disease. In: Billingham FH, Donaldson MC, editors. Third Symposium on Parkinson’s Disease, Churchill Livingstone, Edinburgh; 1969. p. 152–7.
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson’s disease: A base‐line analysis of the DAT ATOP cohort. Neurology 1990;40:1529–34.
Kotagal V, Muller M, Bohnen N. Progression to Advanced Scores on the Hoehn and Yahr Scale in Parkinson Disease Is Not Explained by Degree of Dopaminergic Denervation (P06. 084).
Tang G, Xie H, Xu L, Hao Y, Lin D, Ren D. Genetic study of Apolipoprotein E gene, alpha‐1 antichymotrypsin gene in sporadic Parkinson disease. Am J Med Genet 2002;114:446–9.
Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, et al. APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson’s disease in a Japanese population. J Neural Transm (Vienna) 2011;118:1335–44.
Li J, Luo J, Liu L, Fu H, Tang L. The genetic association between apolipoprotein E gene polymorphism and Parkinson disease: A meta-Analysis of 47 studies. Medicine (Baltimore) 2018;97:e12884.
Ezquerra M, Campdelacreu J, Gaig C, Compta Y, Muñoz E, Martí MJ, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease. Neurosci Lett 2008;448:20–3.
Vefring H, Haugarvoll K, Tysnes OB, Larsen JP, Kurz MW; Norwegian ParkWest Study Group. The role of APOE alleles in incident Parkinson’s disease. The Norwegian ParkWest Study. Acta Neurol Scand 2010;122:438–41.
Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association between APOE and Parkinson’s disease. Neurobiol Dis 2012;46:389–92.
Gregório ML, Pinhel MA, Sado CL, Longo GS, Oliveira FN, Amorim GS, et al. Impact of genetic variants of apolipoprotein E on lipid profile in patients with Parkinson’s disease. Biomed Res Int 2013;2013:641515.
Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson’s disease. Neurology 2000;55:533–8.
Yan W, Wei P, Xuan Y, Guo Y, Li X, Song Y, et al. Relationship between apolipoprotein E gene polymorphism and Parkinson’s disease: A meta-analysis. Int J Clin Exp Med 2016;9:5334–46.
Sun R, Yang S, Zheng B, Liu J, Ma X. Apolipoprotein E polymorphisms and Parkinson disease with or without dementia: A meta-analysis including 6453 participants. J Geriatr Psychiatry Neurol 2019;32:3–15.
Blazquez L, Otaegui D, Saenz A, Paisan-Ruiz C, Emparanza JI, Ruiz-Martinez J, et al. Apolipoprotein E ɛ4 allele in familial and sporadic Parkinson’s disease. Neurosci Lett 2006;406:235–9.
López M, Guerrero J, Yescas P, Boll MC, Familiar I, Ochoa A, et al. Apolipoprotein E ε4 allele is associated with Parkinson disease risk in a Mexican Mestizo population. Mov Disord 2007;22:417–20.
Gao J, Huang X, Park Y, Liu R, Hollenbeck A, Schatzkin A, et al. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging 2011;32:2106.e1-6.
Huang X, Chen PC, Poole C. APOE-ε2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 2004;62:2198–202.
Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J Neurol 2009;256:493–8.
Iwaki H, Blauwendraat C, Leonard HL, Kim JJ, Liu G, Maple-Grødem J, et al. Genome-wide association study of Parkinson’s disease progression biomarkers in 12 longitudinal patients’ cohorts. BioRxiv 2019:585836. doi: 10.1101/585836.
Tan MMX, Lawton MA, Jabbari E, Reynolds RH, Iwaki H, Blauwendraat C, et al. Genome‐wide association studies of cognitive and motor progression in Parkinson’s disease. Mov Disord 2021;36:424–33.
Feldman B, Chapman J, Korczyn AD. Apolipoprotein ɛ4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand 2006;113:14–7.
Pavlova R, Petrova M, Zhelev Y, Boyadzhieva E, Belcheva O, Traykov L. Apolipoprotein E ε4 and motor symptoms in patients with late-onset Parkinson’s disease. Med Pregl/Med Rev 2013;49:57–62.
Pavlova R, Mehrabian S, Petrova M, Skelina S, Mihova K, Jordanova A, et al. Cognitive, neuropsychiatric, and motor features associated with apolipoprotein E ε4 allele in a sample of Bulgarian patients with late-onset Parkinson’s disease. Am J Alzheimers Dis Other Demen 2014;29:614–9.
Mengel D, Dams J, Ziemek J, Becker J, Balzer-Geldsetzer M, Hilker R, et al. Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson’s disease. Parkinsonism Relat Disord 2016;29:112–6.
Ghebremedhin E, Tredici KD, Vuksic M, Rüb U, Thal DR, Burbach GJ, et al. Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol 2006;65:116–23.
Zareparsi S, Camicioli R, Sexton G, Bird T, Swanson P, Kaye J, et al. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet 2002;107:156–61.
Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009;124:593–605.
Ikeda T, Sugiuchi H, Senba U, Shibuya Y, Uji Y, Okabe H, et al. Preliminary findings on the variation of serum apolipoprotein levels in neural degenerative disorders. J Clin Lab Anal 1993;7:1–4.
Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, et al. α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients. Proc Natl Acad Sci 2019;116:15226–35.
Wilhelmus MM, Bol JG, Van Haastert ES, Rozemuller AJ, Bu G, Drukarch B, et al. Apolipoprotein E and LRP1 increase early in Parkinson’s disease pathogenesis. Am J Pathol 2011;179:2152–6.
Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, et al. APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med 2020;12:eaay1809.
Vijayaraghavan S, Maetzler W, Reimold M, Lithner CU, Liepelt-Scarfone I, Berg D, et al. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. Alzheimers Dement 2014;10:530–40.
MacAulay RK, Allaire T, Brouillette R, Foil H, Bruce-Keller AJ, Keller JN. Apolipoprotein E genotype linked to spatial gait characteristics: Predictors of cognitive dual task gait change. PLoS One 2016;11:e0156732.
Sakurai R, Montero-Odasso M. Apolipoprotein E4 allele and gait performance in mild cognitive impairment: Results from the gait and brain study. J Gerontol A Biol Sci Med Sci 2017;72:1676–82.
Fereshtehnejad SM, Postuma RB. Subtypes of Parkinson’s disease: What do they tell us about disease progression? Curr Neurol Neurosci Rep 2017;17:34.
Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, et al. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol 2014;127:621–32.
المشرفين على المادة: 0 (Apolipoproteins E)
0 (ApoE protein, human)
تواريخ الأحداث: Date Created: 20240501 Date Completed: 20240501 Latest Revision: 20240702
رمز التحديث: 20240702
DOI: 10.4103/ni.ni_940_21
PMID: 38691476
قاعدة البيانات: MEDLINE
الوصف
تدمد:1998-4022
DOI:10.4103/ni.ni_940_21